BTIG is joining in on the slew of analyst coverage for Relypsa (Nasdaq: RLYP) today.Analyst Timothy Chiang commented today: This ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA

Flynn's Deerfield Management Raises Stake in Relypsa (RLYP) to 5.28%May 27, 2016 8:21 AM Form SC 13G Relypsa Inc Filed by: Flynn James EMay 27, 2016 8:01 AM Relypsa (RLYP) to Trade Toward Takeover Valuation After Competitor Delay - MizuhoMay 27, 2016 7:22 AM AstraZeneca's CRL on ZS-9 Reduces Near Term Commercial Risk for Veltassa and Relypsa (RLYP) - WedbushMay 27, 2016 6:34 AM Relypsa (RLYP) Surges Higher After AstraZeneca's ZS-9 Receives CRL from FDAMay 27, 2016 6:18 AM AstraZeneca (AZN) Receives CRL on ZS-9May 27, 2016 6:14 AM Relypsa (RLYP) volatility elevated ahead of FDA decision on AstraZeneca (AZN) competing drugMay 27, 2016 6:04 AM Relypsa (RLYP) Ticks Higher Ahead of FDA on ZS-9May 26, 2016 4:38 PM Relypsa (RLYP) Seeks Label Change for VeltassaMay 25, 2016 4:17 PM Relypsa Submits Supplemental New Drug Application to FDA Requesting Label Changes for Veltassa Based on Phase 1 Drug-Drug Interaction StudiesMay 25, 2016 4:16 PM Relypsa (RLYP) Gains Ahead of Binary EventMay 25, 2016 11:04 AM